John E Godwin MD

Hematologic Oncology

Physician

Summary

Dr. John Godwin is an oncologist in Portland, OR and is affiliated with multiple hospitals in the area, including Providence Milwaukie Hospital, Providence Newberg Medical Center, Providence Portland Medical Center, Providence St. Vincent Medical Center, and Providence Willamette Falls Medical Center. He received his medical degree from University of Alabama School of Medicine and has been in practice 43 years. He specializes in hematologic oncology and is experienced in acute myeloid leukemia and ovarian cancer. He has more than 100 publications and over 500 citings.

University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 1983 - 1985
Baylor College of MedicineResidency, Internal Medicine, 1979 - 1983
Baylor College of MedicineInternship, Transitional Year, 1978 - 1979
University of Alabama School of MedicineClass of 1978

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017

PubMed

3 citations
Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study.
Alison Sehgal, Daanish Hoda, Peter A Riedell, Nilanjan Ghosh, Mehdi Hamadani
Blood Advances. 2025-08-12
3 citations
A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis.
Chenyu Lin, Anand A Patel, Dezheng Huo, Theodore Karrison, Koen van Besien
Blood Advances. 2024-11-26
8 citations
A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.
Alain P Algazi, James Moon, Christopher D Lao, Bartosz Chmielowski, Kari L Kendra
Cancer. 2024-05-15

Journal Articles

Second Cycle Remission Achievement with 7+3 and Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials
Brent L Wood, Roland B Walter, John E Godwin, James K Weick, Elihu H Estey, Derek L Stirewalt, Frederick R Appelbaum, Nature

Abstracts/Posters

Increasing Lengths of First Complete Remission with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial Data
John E. Godwin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report
John E. Godwin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particular...
John E. Godwin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart¬ Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associat...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

MacroGenics : Flotetuzumab (CD123 X CD3) as Salvage Therapy for PIF and ER AML (Aldoss)December 7th, 2020
The Hunt for a CRISPR Antidote Just Heated UpMay 21st, 2019